Food protein hydrolysates as a source of dipeptidyl peptidase IV inhibitory peptides for the management of type 2 diabetes

• Published in: Proceedings of the Nutrition Society Vol. 73; no. 1; pp. 34 - 46
• Main Authors: Power, Orla, Nongonierma, A. B., Jakeman, P., FitzGerald, R. J.
• Format: Journal Article Conference Proceeding
• Language: English
• Published: Cambridge, UK Cambridge University Press 01.02.2014
• Subjects: Amino acids; Animals; Biological and medical sciences; blood glucose; Blood Glucose - metabolism; Diabetes; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - diet therapy; Diabetes Mellitus, Type 2 - drug therapy; Diabetes. Impaired glucose tolerance; Dietary Proteins - therapeutic use; Dipeptidyl Peptidase 4 - blood; dipeptidyl-peptidase IV; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use; drugs; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Enzymes; Etiopathogenesis. Screening. Investigations. Target tissue resistance; Food; gastric inhibitory polypeptide; Gastric Inhibitory Polypeptide - blood; Glucagon; glucagon-like peptide 1; Glucagon-Like Peptide 1 - blood; Glucose; half life; Hormones; Humans; Hypoglycemic Agents - pharmacology; Hypoglycemic Agents - therapeutic use; Inhibitors; Insulin resistance; Irish Section Postgraduate Meeting; Medical sciences; Milk; milk proteins; Milk Proteins - therapeutic use; Natural & organic foods; noninsulin-dependent diabetes mellitus; nutritional intervention; Peptides; Peptides - pharmacology; Peptides - therapeutic use; Physiology; Polypeptides; protein hydrolysates; Protein Hydrolysates - pharmacology; Protein Hydrolysates - therapeutic use; Proteins; Small intestine; structure-activity relationships; United States > US; Milk protein; Glucose-dependent insulinotropic polypeptide; Hydrolysate; Dipeptidyl peptidase IV inhibition; Functional foods; Bioactive peptide; Glucagon like peptide-1; Type 2 diabetes mellitus; Endocrinopathy; Type 2 diabetes; Enzyme; Metabolic diseases; Glucagon like peptide 1; Peptidases; Gastrointestinal hormone; Health food; Hydrolases; Inhibition; Gastric inhibitory peptide

The prevalence of type 2 diabetes mellitus (T2DM) is increasing and it is estimated that by 2030 approximately 366 million people will be diagnosed with this condition. The use of dipeptidyl peptidase IV (DPP-IV) inhibitors is an emerging strategy for the treatment of T2DM. DPP-IV is a ubiquitous am...